Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2018 / Cilt: 26 - Sayı: 3

Long-term outcomes of Omniflow II biosynthetic vascular graft in lower extremity arterial revascularization

Omniflow II biyosentetik vasküler greftin alt ekstremite arteriyel revaskülarizasyonunda uzun dönem sonuçları

Pages
407–413
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These grafts may be prefered due to high patency rates, low incidence of aneursym formations, and infections.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: This study aims to evaluate the patency rates and long-term outcomes of femoro-popliteal bypass procedures with Omniflow II biosynthetic vascular grafts in patients with occlusive vascular disease.Methods: This retrospective, observational, clinical study included a total of 93 patients (61 males, 32 females; mean age 56.9±7.4 years; range, 43 to 83 years) who underwent femoro-popliteal bypass in which Omniflow II biosynthetic vascular grafts were used due to peripheral arterial disease.
📊
Key Findings & Data:The patients were divided into two groups: 62 patients undergoing femoro-popliteal above-knee bypass and 31 patients undergoing the femoro-popliteal below-knee bypass.
💡
Conclusion & Impact:These grafts may be prefered due to high patency rates, low incidence of aneursym formations, and infections.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: This study aims to evaluate the patency rates and long-term outcomes of femoro-popliteal bypass procedures with Omniflow II biosynthetic vascular grafts in patients with occlusive vascular disease.Methods: This retrospective, observational, clinical study included a total of 93 patients (61 males, 32 females; mean age 56.9±7.4 years; range, 43 to 83 years) who underwent femoro-popliteal bypass in which Omniflow II biosynthetic vascular grafts were used due to peripheral arterial disease. The patients were divided into two groups: 62 patients undergoing femoro-popliteal above-knee bypass and 31 patients undergoing the femoro-popliteal below-knee bypass. We evaluated preoperative clinical characteristics, postoperative graft patency rates, and other clinical results.Results: The mean follow-up was 44.9±18.8 months in the femoro-popliteal above-knee bypass group and 47.3±22.3 months in the femoro-popliteal below-knee bypass group (p=0.302). The cumulative primary graft patency rates of the femoro-popliteal above-knee bypass and femoro-popliteal below-knee bypass groups at three, four, and five years were 98%, 95% and 78% and 86%, 75% and 45%, respectively (log-rank; p=0.312). The cumulative assisted graft patency rates of the femoro-popliteal above-knee bypass and femoro-popliteal below-knee bypass groups at five years were 87.9% and 65.3%, respectively (log-rank; p=0.530).Conclusion: The Omniflow II biosynthetic vascular graft is suitable for above- and below-knee femoro-popliteal bypass procedures. These grafts may be prefered due to high patency rates, low incidence of aneursym formations, and infections.

Özet

Amaç: Bu çalışmada tıkayıcı damar hastalığı olan hastalarda Omniflow II biyosentetik vasküler greftler ile femoropopliteal baypas işlemlerinin açıklık oranı ve uzun dönem sonuçları değerlendirildi. Çalış­ma­ planı:­ Bu retrospektif, gözlemsel, klinik çalışmaya periferik arter hastalığı nedeniyle Omniflow II biyosentetik vasküler greftlerin kullanıldığı femoropopliteal baypas yapılan toplam 93 hasta (61 erkek, 32 kadın; ort. yaş 56.9±7.4 yıl; dağılım, 43-83 yıl) alındı. Bu hastalar iki gruba ayrıldı: femoropopliteal diz üstü baypas yapılan 62 hasta ve femoropopliteal diz altı baypas yapılan 31 hasta. Ameliyat öncesi klinik özellikler, ameliyat sonrası greft açıklık oranları ve diğer klinik bulgular değerlendirildi. Bulgular: Ortalama takip süresi femoropopliteal diz üstü baypas grubunda 44.9±18.8 ay ve femoropopliteal diz altı baypas grubunda 47.3±22.3 ay idi (p=0.302). Üç, dört ve beşinci yıllarda femoropopliteal diz üstü baypas ve femoropopliteal diz altı baypas grubunda kümülatif primer greft açıklık oranları sırasıyla %98, %95 ve %78 ve %86, %75 ve %45 idi (log-rank; p=0.312). Beşinci yılda femoropopliteal diz üstü baypas ve femoropopliteal diz altı baypas grubunda kümülatif yardımlı greft açıklık oranları sırasıyla %87.9 ve %65.3 idi (log-rank; p=0.530). Sonuç:­ Omniflow II biyosentetik vasküler greft, femoropopliteal diz üstü ve diz altı baypas işlemlerinde kullanılabilir. Bu greftler yüksek açıklık oranları, düşük anevrizma ve enfeksiyon gelişim insidansı nedeniyle tercih edilebilir.

🔖

Cite This Article

GÖNCÜ, M. T., YAVUZ, Ş., ÖZSİN, K. K., ÇAYIR, M. Ç., TOKTAŞ, F. (2022). Long-term outcomes of Omniflow II biosynthetic vascular graft in lower extremity arterial revascularization. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 26 - Sayı: 3, 407–413. https://ajindex.com/articles/423912

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Nakajima N, Hayashida N, Kubo Y, Sasajima T, Katsumura T, Masaki H, et al. The clinical trial of a vascular prosthesis for lower leg ischemia. Jpn J Vasc Surg 1996
  2. Jakobsen HL, Baekgaard N, Christoffersen JK. Below-knee popliteal and distal bypass with PTFE and vein cuff. Eur J Vasc Endovasc Surg 1998
  3. Yoshida H, Sasajima T, Goh K, Inaba M, Otani N, Kubo Y. Early results of a reinforced biosynthetic ovine collagen vascular prosthesis for small arterial reconstruction. Surg Today 1996
  4. Karaca K, Özeren M, Aytaçoğlu BN, Vezir Ö, Sucu N. Ringed reinforced polytetrafluoroethylene sheltered saphenous vein graft for femorofemoral bypass in critical leg ischemia with limited distal run off: Case Report. Damar Cer Derg 2016
  5. Mamode N, Scott RN. Graft type for femoro-popliteal bypass surgery. Cochrane Database Syst Rev 2000
  6. CD001487. 16. Kurç E, Enç Y, Çınar B, Kurç P, Kösem M, Sezerman Ö. Graft material selection in femoropopliteal bypass surgery and results of long term graft patency. Turk Gogus Kalp Dama 2000
  7. van der Slegt J, Steunenberg SL, Donker JM, Veen EJ, Ho GH, de Groot HG, et al. The current position of precuffed expanded polytetrafluoroethylene bypass grafts in peripheral vascular surgery. J Vasc Surg 2014
  8. Ramshaw J, Werkmeister J, Edwards G. Tissue-polymer composite vascular prostheses. In: Wise D, Trantolo D, Altobelli D, Yaszenski M, Gresser J, Schwartz E, editors. Encyclopedic Handbook of Biomaterials and Bioengineering, Part B: Applications. New York: Marcel Dekker Inc.
  9. p. 953-78. 13. Amann W, Tiesenhausen K, Fruhwirth J, Thalhammer M, Allmayer T, Tomka M, et al. Graft aneurysms after biosynthetic vascular replacement. Z. Herz- Thorax-Gefäßchir 2000
  10. Wang SS, Chu SH. Clinical use of omniflow vascular graft as arteriovenous bridging graft for hemodialysis. Artif Organs 1996
  11. Koch G, Gutschi S, Pascher O, Fruhwirth H, Glanzer H. Analysis of 274 Omniflow Vascular Prostheses implanted over an eight-year period. Aust N Z J Surg 1997
  12. Neufang A, Espinola-Klein C, Dorweiler B, Messow CM, Schmiedt W, Vahl CF. Femoropopliteal prosthetic bypass with glutaraldehyde stabilized human umbilical vein (HUV). J Vasc Surg 2007
  13. Dardik I, Ibrahim I, Dardik H. Femoral popliteal bypass employing modified human umbilical cord vein: an assessment of early clinical results. Cardiovasc Dis 1976
  14. Kovalic AJ, Beattie D